Tampa Bay Business Journal – April 6
A $75 million investment from media giant Hearst last year gave M2Gen the capital to help the network of cancer centers expand so it can collect more and different kinds of patient data that could lead to better outcomes. Because mutations make each person’s cancer unique to them, a vast amount of data is needed.
Medscape – April 5
One of the editorialists, Howard L. McLeod, PharmD, Moffitt Cancer Center, Tampa, Florida, told Medscape Medical News, "This new gene test is not perfect. It doesn't completely eliminate these adverse reactions, but it's a lot better than we what we have at the moment, which is just hoping for the best."
Tampa Bay Newspapers – April 6
This year’s game will benefit Kyle Resler, a 20-year veteran of the Clearwater Police Department and Navy veteran. In November, Resler was diagnosed with Stage 4 high grade neuroendocrine carcinoma, an extremely rare cancer that currently has no cure. The father of two and Countryside High School graduate is currently undergoing chemotherapy treatment at Moffitt Cancer Center.
Culpepper will undergo five hours of treatment for five days, three more times, alternating cycles at Upstate and at Moffitt Cancer Center in Tampa.
WSYR – April 5
After being diagnosed here in Syracuse, Culpepper flew home to Tampa, Florida to have emergency surgery last month at the renowned Moffitt Cancer Center.
Syracuse.com – April 5
Culpepper is in the middle of a two-week break in his chemotherapy treatments. He will undergo five hours of treatment for five days, three more times, alternating cycles at Upstate and at Moffitt Cancer Center in Tampa.
USC News – April 5
After completing his PhD in mechanical engineering in August, West is now working as a postdoctoral researcher for the Moffitt Cancer Center in Florida. Working in the Integrative mathematical oncology department, he is using the mathematical model to test treatment plans being developed by clinicians at the center before they are applied to patients during clinical trials.
Plant City Observer – April 5
The Country Wood Golfers had a record breaking year at their annual golf tournament fundraisers and donated $10,000 to Moffitt Cancer Center.
Boca Newspaper – April 5
Finally, Kole was examined by Dr. Peter Romano in Coconut Creek. The doctor’s physician assistant saw an anomaly on an X-ray and followed up with an MRI. Kole was rushed to Moffitt Cancer in Tampa for immediate treatment of osteosarcoma. “Dr. Romano arranged everything,” said the boy’s relieved dad.
Renal and Urology News – April 4
Using their institutional database spanning over 25 years, Kosj Yamoah, MD, PhD, and colleagues from the Moffitt Cancer Center & Research Institute in Tampa, Florida, evaluated prostate cancer (PCa) outcomes and ruled out some known confounders. Of 7307 patients diagnosed with PCa during 1989 to 2015, 432 died from their disease.
Tampa Bay Times – April 4
The interest in sharks at the time also led to a collaboration with the Moffitt Cancer Center, a partnership that Luer hoped would push the research over a hurdle that had stalled their progress for nearly 15 years. While Luer and Walsh had discovered that the immune cells were able to attack the cancer, they couldn’t pinpoint just what it was the cells were producing that triggered that kind of response.
Cancer Network – April 4
“To date, CAR T-cell trials have thus far shown the highest rate of complete and minimal residual disease remission rates of any other agent,” explained Bijal Shah, MD, of Moffitt Cancer Center in Tampa, during the National Comprehensive Cancer Network (NCCN) Annual Conference, held March 22–24 in Orlando, Florida.
Bioniz Therapeutics Initiates Phase 1/2 Clinical Study of BNZ‑1 in T-Cell Leukemia and Lymphoma Markets Insider – April 4
The study includes a 3-month treatment extension for all patients to further evaluate safety and clinical response. The study is enrolling patients at Ohio State University, the University of Virginia, Moffitt Cancer Center and City of Hope Cancer Center. More information about this study can be found at www.clinicaltrials.gov, Identifier NCT03239392.
OncLive – April 3
Jonathan R. Strosberg, MD: NETTER-1 was the first randomized phase III study of peptide receptor radiotherapy of a radiolabeled somatostatin analog. The population studied was patients with midgut neuroendocrine tumors—midgut means small intestine, jejunoileum, proximal colon, and cecum.
Cure Magazine – April 3
CURE spoke with two authors on the study, Philipp M. Altrock, Ph.D., assistant member at Moffitt Cancer Center’s Department of Intergraded Mathematical Oncology, and Michael M. Tomasson, M.D., of the Roy J. and Lucille A. Carver College of Medicine at the University of Iowa, about their findings.
Science Newsline Medicine – April 3
Moffitt Cancer Center researchers are using a unique approach by combining typical cell culture studies with mathematical modeling to determine how heterogeneity within a tumor and the surrounding tumor environment affect responses to targeted drug therapies. Their study was published online in PLOS Biology.
Osprey Observer – April 2
There will be a wide variety of opportunities for those of all passions and interests. These companies include, but are not limited to: Bank of America, Amazon, Hillsborough County Public Schools, Twin Creeks Assisted Living, Express Employment, Goodwill, Affinity, New Horizons, DACCO, Moffitt Cancer Center, and Quest Inc., along with many more.
BrinkWire – March 31
Only half of patients with multiple myeloma are expected to survive five years after their diagnosis. Moffitt Cancer Center researchers are trying to identify patients who are at a higher risk of developing multiple myeloma early in order to improve patient outcomes.
OncLive – March 30
Hung T. Khong, MD, medical oncologist, Moffitt Cancer Center, discusses the use of neoadjuvant endocrine therapy.
OncLive – March 30
Heather S. Han, MD, research director, medical oncologist, Department of Breast Oncology, Moffitt Cancer Center, discusses the differences between CDK 4/6 inhibitors and their efficacy as both single- and combination agents.
Syracuse.com – March 30
"My life has always been a routine," Culpepper told Moffitt Cancer Center, where he is receiving treatment. "It's been about getting better every day, so I think that mindset definitely puts me at an advantage with what I am up against."
College Spun – March 30
Looking ahead, Culpepper plans to alternate chemotherapy cycles at Moffitt Cancer Center in Tampa, Fla., his hometown, and an undisclosed New York hospital. That way he can keep up with his academics and spend as much time with the SU football program as possible.
AJMC – March 30
Bijal Shah, MD, of Moffitt Cancer Center, said that patients with ALL seem to have higher rates of neurologic toxicity when treated with CAR T-cell agents than do patients with other cancers. This observation suggests that there are some disease features of ALL that are linked with adverse events.
Please note we cannot guarantee the accuracy or availability of links. The stories belong to the respective publishers, and links may expire. Some news sites require you to register and select a password in order to retrieve articles, but most usually do not charge a fee to retrieve these news stories.